Opendata, web and dolomites

Pro-Staph-ID

Clinical biomarker and rapid diagnostic test for Staphylococcus aureus induced ventilator-associated pneumonia

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "Pro-Staph-ID" data sheet

The following table provides information about the project.

Coordinator
Arsanis Biosciences, GmbH 

Organization address
address: Helmut-Qualtinger Gasse 2
city: WIEN
postcode: 1030
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Austria [AT]
 Project website http://www.arsanis.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2014
 Funding Scheme SME-1
 Starting year 2014
 Duration (year-month-day) from 2014-10-01   to  2014-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    Arsanis Biosciences, GmbH AT (WIEN) coordinator 50˙000.00

Map

 Project objective

Hospital acquired infections such as ventilator associated pneumonia (VAP) are associated with unacceptably high mortality rates and spiraling healthcare costs. Staphylococcus aureus (S. aureus) is a major human pathogen, and one of the leading causes of VAP and other nosocomial infections. Vital to the effective management and treatment of S. aureus VAP is the use of appropriate antimicrobial therapies, and ideally prophylactic measures. Antibiotic stewardship efforts, aimed to reduce the spread of antibiotic resistance, are resulting in changing clinical guidelines so the causative pathogen is identified before antibiotic treatment is initiated. Such approaches rely on diagnostic measures to identify the infecting bacteria and resistance pattern, and usually take over 24 hours to complete. Therefore, early identification of patients at risk of developing VAP coupled with characterization of the causative pathogen would allow early treatment and potential prevention, ultimately translating to reduced mortality and healthcare cost.

The overall aim of this project is the clinical validation of a novel biomarker identified by Arsanis Biosciences to identify patients likely to develop S. aureus induced VAP. In parallel, we aim to develop a unique rapid diagnostic test incorporating this biomarker and detecting other markers to characterize the bacteria, for use to at the bedside to identify these ‘at risk’ patients in the intensive care unit (ICU). The test is aimed to give the ICU clinician rapid information to inform early clinical intervention.

During the feasibility study we will assess the market and clinical utility of the diagnostic test through dialogue with KOLs, healthcare professionals and end users from a range of EU hospitals. We will also validate the format and design of the diagnostic kit, and design a road-map for clinical study and approval. We will also assess pricing and reimbursement issues and complete FTO analysis for the concept.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PRO-STAPH-ID" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PRO-STAPH-ID" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

PanCareFollowUp (2019)

PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregivers

Read More  

GACD (2019)

Global Alliance for Chronic Diseases Secretariat

Read More  

LEGACy (2019)

CeLac and European consortium for a personalized medicine approach to Gastric Cancer

Read More